Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
暂无分享,去创建一个
J. Isaacsohn | R. Goldstein | V. Miller | L. Shurzinske | S. Weiss | M. Davidson | W. Brown | J. Davignon | J Davignon | S R Weiss | J L Isaacsohn | R G Bakker-Arkema | M H Davidson | R J Goldstein | L M Keilson | W V Brown | V T Miller | L J Shurzinske | D M Black | D. Black | R. Bakker-Arkema | L. Keilson | M. H. Davidson
[1] S. Grundy,et al. Combination drug therapy for familial combined hyperlipidemia. , 1988, Annals of internal medicine.
[2] M. Heimberg,et al. Effects of free fatty acids on activity of hepatic microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase and on secretion of triglyceride and cholesterol by liver. , 1977, The Journal of biological chemistry.
[3] S. Grundy,et al. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. , 1992, Archives of internal medicine.
[4] Y. Hall,et al. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I. Use of a dietary monitoring tool. , 1980, Journal of the American Dietetic Association.
[5] J. Fruchart,et al. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. , 1990, Clinical chemistry.
[6] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[7] D. Sprecher,et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[8] J. Albers,et al. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.
[9] D R Jacobs,et al. Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. , 1982, American journal of epidemiology.
[10] G. Schonfeld,et al. Apolipoprotein A-II content of human plasma high density lipoproteins measured by radioimmunoassay. , 1977, Journal of lipid research.
[11] Richard H. Myers,et al. Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.
[12] T. Südhof,et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[13] D Feskanich,et al. Comparison of a computerized and a manual method of food coding for nutrient intake studies. , 1988, Journal of the American Dietetic Association.
[14] J. D. Proctor,et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. , 1994, JAMA.
[15] Plasma triglyceride and coronary heart disease. , 1991 .
[16] R. Leboeuf,et al. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. , 1992, Journal of lipid research.
[17] R. Bawol,et al. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. , 1980, The New England journal of medicine.